- Home
- IAG vs APLS Comparison
IAG vs APLS Comparison
Compare IAG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAG
- APLS
- Stock Information
- Founded
- IAG 1990
- APLS 2009
- Country
- IAG Canada
- APLS United States
- Employees
- IAG N/A
- APLS N/A
- Industry
- IAG Precious Metals
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- IAG Basic Materials
- APLS Health Care
- Exchange
- IAG Nasdaq
- APLS Nasdaq
- Market Cap
- IAG 3.7B
- APLS 3.3B
- IPO Year
- IAG 1996
- APLS 2017
- Fundamental
- Price
- IAG $5.70
- APLS $19.94
- Analyst Decision
- IAG Buy
- APLS Buy
- Analyst Count
- IAG 7
- APLS 18
- Target Price
- IAG $7.49
- APLS $45.59
- AVG Volume (30 Days)
- IAG 12.4M
- APLS 2.1M
- Earning Date
- IAG 05-08-2025
- APLS 05-06-2025
- Dividend Yield
- IAG N/A
- APLS N/A
- EPS Growth
- IAG 677.20
- APLS N/A
- EPS
- IAG 1.50
- APLS N/A
- Revenue
- IAG $1,633,000,000.00
- APLS $781,367,000.00
- Revenue This Year
- IAG $38.27
- APLS $12.85
- Revenue Next Year
- IAG $6.29
- APLS $20.78
- P/E Ratio
- IAG $4.36
- APLS N/A
- Revenue Growth
- IAG 65.43
- APLS 97.02
- 52 Week Low
- IAG $3.44
- APLS $21.70
- 52 Week High
- IAG $6.69
- APLS $58.12
- Technical
- Relative Strength Index (RSI)
- IAG 53.40
- APLS 30.79
- Support Level
- IAG $5.95
- APLS $21.70
- Resistance Level
- IAG $6.54
- APLS $23.23
- Average True Range (ATR)
- IAG 0.27
- APLS 1.21
- MACD
- IAG 0.04
- APLS -0.10
- Stochastic Oscillator
- IAG 44.53
- APLS 2.58
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Burkina Faso - Essakane mine, Canada - Doyon division, including Westwood mine. The company's s non-gold mine segments are the Cote Gold project, Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Burkina Faso segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.